Stock 1541 IMMUNEONCO BIOPHARMACEUTICALS (SHANGHAI) INC.
Add to a list
To use this feature you must be a member
Log inSign up

Ratings ImmuneOnco Biopharmaceuticals (Shanghai) Inc.

Equities

1541

CNE100006624

Delayed Hong Kong S.E.
Other stock markets
 22:42:34 2024-06-16 EDT 		5-day change 1st Jan Change
14.6 HKD +0.14% Intraday chart for ImmuneOnco Biopharmaceuticals (Shanghai) Inc. -1.22% -51.17%
06-03 ImmuneOnco Biopharmaceuticals Gets China's Phase 3 Trial Approval for Leukemia Drug MT
05-30 ImmuneOnco Completes Filing with China Regulator for Conversion of H Shares MT

Summary

  • Overall, the company has poor fundamentals for a medium to long-term investment strategy.

Strengths

  • Analysts expect a sharply increasing business volume for the group, with high growth rates in the coming years.

Weaknesses

  • As a percentage of sales and without taking into account depreciation and amortization, the company has relatively low margins.
  • The company is in a hindered financial situation with significant debt and rather low EBITDA levels.
  • The company's "enterprise value to sales" ratio is among the highest in the world.
  • For the last twelve months, the trend in sales revisions has been clearly going down, which emphasizes downgraded expectations from the analysts.
  • The sales outlook for the group was lowered in the last twelve months. This change in forecast points out a decline in activity as well as pessimistic analyses of the company.
  • The average price target of analysts who are interested in the stock has been significantly revised downwards over the last four months.

Ratings chart - Surperformance

Sector: Biotechnology & Medical Research

1st Jan change Capi. Investor Rating ESG Refinitiv
IMMUNEONCO BIOPHARMACEUTICALS (SHANGHAI) INC. Stock ImmuneOnco Biopharmaceuticals (Shanghai) Inc.
-51.17% 698M -
VERTEX PHARMACEUTICALS INCORPORATED Stock Vertex Pharmaceuticals Incorporated
+18.15% 124B
B+
REGENERON PHARMACEUTICALS, INC. Stock Regeneron Pharmaceuticals, Inc.
+18.02% 112B
B+
ARGENX SE Stock argenx SE
+5.07% 22.94B
B
BIONTECH SE Stock BioNTech SE
-12.75% 22.22B
B+
BEIGENE, LTD. Stock BeiGene, Ltd.
-9.86% 17.02B
B
GENMAB A/S Stock Genmab A/S
-14.97% 16.88B
A-
WUXI APPTEC CO., LTD. Stock WuXi AppTec Co., Ltd.
-39.94% 16.87B
A-
NEUROCRINE BIOSCIENCES, INC. Stock Neurocrine Biosciences, Inc.
+2.80% 13.63B
C+
SAREPTA THERAPEUTICS, INC. Stock Sarepta Therapeutics, Inc.
+27.39% 11.61B
C+
Investor Rating
Trading Rating
-
ESG Refinitiv
-

Financials

Sales growth
Earnings Growth
-
EBITDA / Sales
Profitability
-
Finances

Valuation

P/E ratio
-
EV / Sales
Price to Book
-
Price to Free Cash Flow
-
Yield
-

Momentum

1 year Revenue revision
4 months Revenue revision
7 days Revenue revision
1 year EPS revision
-
4 months EPS revision
-

Consensus

Analyst Opinion
Potential Price Target
4m Target Price Revision
4m Revision of opinion
-
12m Revision of opinion
-

Business Predictability

Analyst Coverage
Divergence of Estimates
-
Divergence of analysts' opinions
-
Divergence of Target Price
-
Earnings quality
-

Technical analysis

ST Timing
MT Timing
LT Timing
RSI
Bollinger Spread
Unusual volumes
  1. Stock Market
  2. Equities
  3. 1541 Stock
  4. Ratings ImmuneOnco Biopharmaceuticals (Shanghai) Inc.